LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers)

This publication has 28 references indexed in Scilit:

• Dose Dependence of Emergence of Resistance to Linezolid inEnterococcus faecalisIn Vivo
  The Journal of Infectious Diseases, 2007
• Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus aureus encountered in the outpatient setting
  Diagnostic Microbiology and Infectious Disease, 2006
• Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations
  Journal of Antimicrobial Chemotherapy, 2005
• In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program
  Antimicrobial Agents and Chemotherapy, 2005
• Trends in linezolid susceptibility patterns: report from the 2002–2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program
  International Journal of Antimicrobial Agents, 2005
• Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin
  Intensive Care Medicine, 2004
• Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program
  Clinical Infectious Diseases, 2003
• Oxazolidinone antibiotics
  The Lancet, 2001
• Methicillin-Resistant Staphylococcus aureus Infection in a Renal Allograft Recipient Treated Successfully with a Novel New Antimicrobial Agent (Linezolid): New Treatment Options for Infections Due to Resistant Organisms
  Clinical Infectious Diseases, 1999
• Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada
  New England Journal of Medicine, 1999